The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided silver bullet (dnG1 killer gene) to the cancer clinic with Expanded Access in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of informed consent, this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors-validating pathotropic (disease-seeking) tumor targeting avant la lettre.